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Inhibition of Lipopolysaccharide Transport to the Outer
Membrane in Pseudomonas aeruginosa by Peptidomimetic
Antibiotics
Martina Werneburg,[a] Katja Zerbe,[a] Mario Juhas,[b] Laurent Bigler,[a] Urs Stalder,[a]
Andres Kaech,[c] Urs Ziegler,[c] Daniel Obrecht,[d] Leo Eberl,[b] and John A. Robinson*[a]
Introduction
A family of macrocyclic peptidomimetic antibiotics (e.g. , L27–
11, Figure 1A) was shown recently to exhibit potent antimicro-
bial activity against Gram-negative Pseudomonas sp. , including
the problematic human pathogen Pseudomonas aeruginosa. A
photoprobe derived from L27–11 was shown by photoaffinity
labelling to bind to the outer membrane (OM) protein LptD in
P. aeruginosa.[1] LptD fulfils an essential role in OM biogenesis
in many Gram-negative bacteria, where it functions in a com-
plex with the lipoprotein LptE to transport lipopolysaccharide
(LPS) from the periplasm to the outer cell surface (Figure 1B).[2]
LptD is predicted from bioinformatic analysis to contain a C-
terminal b-barrel domain of about 600 residues embedded in
the OM and an N-terminal domain of about 300 residues that
sits on the periplasmic side of the OM.
Resistance to many currently used antibiotics is a growing
problem with P. aeruginosa, caused in part by the permeability
barrier imposed by the asymmetric outer cell membrane,
which comprises LPS in the outer leaflet and phospholipids in
the inner.[3] In this work, we set out to investigate whether the
mechanism of action of L27–11 involves inhibition of LptD-
mediated LPS transport to the outer cell surface in P. aerugino-
sa. Presently, it cannot be excluded that LptD transports the
antibiotic across the OM, so that it can interact with an as yet
unknown target within the cell. Ample evidence exists that b-
barrel OM proteins in Gram-negative bacteria can aid the cellu-
lar uptake of peptide antibiotics, such as microcin J25 and the
colicins.[4] If this hypothesis is correct, however, there should
be no major effects by the antibiotic on LPS transport to the
cell surface. However, changes in Pseudomonas cell morpholo-
gy caused by L27–11 were detected by electron microscopy
(EM) in earlier work, which is consistent with a mechanism of
action that impacts on cell wall biogenesis.[1] So far, no other
molecules have been described that interact with LptD.
For this reason we considered it important to search for ad-
ditional evidence that antibiotic L27–11 inhibits LPS transport
The asymmetric outer membrane (OM) of Gram-negative bac-
teria contains lipopolysaccharide (LPS) in the outer leaflet and
phospholipid in the inner leaflet. During OM biogenesis, LPS is
transported from the periplasm into the outer leaflet by a com-
plex comprising the OM proteins LptD and LptE. Recently,
a new family of macrocyclic peptidomimetic antibiotics that in-
teract with LptD of the opportunistic human pathogen Pseudo-
monas aeruginosa was discovered. Here we provide evidence
that the peptidomimetics inhibit the LPS transport function of
LptD. One approach to monitor LPS transport involved studies
of lipid A modifications. Some modifications occur only in the
inner membrane while others occur only in the OM, and thus
provide markers for LPS transport within the bacterial enve-
lope. We prepared a conditional lptD mutant of P. aeruginosa
PAO1 that allowed control of lptD expression from the rham-
nose promoter. With this mutant, the effects caused by the
antibiotic on the wild-type strain were compared with those
caused by depleting LptD in the mutant strain. When LptD
was depleted in the mutant, electron microscopy revealed ac-
cumulation of membrane-like material within cells and OM
blebbing; this mirrored similar effects in the wild-type strain
caused by the antibiotic. Moreover, the bacterium responded
to the antibiotic, and to depletion of LptD, by introducing the
same lipid A modifications, consistent with inhibition by the
antibiotic of LptD-mediated LPS transport. This conclusion was
further supported by monitoring the radiolabelling of LPS from
[14C]acetate, and by fractionation of IM and OM components.
Overall, the results provide support for a mechanism of action
for the peptidomimetic antibiotics that involves inhibition of
LPS transport to the cell surface.
[a] M. Werneburg, K. Zerbe, L. Bigler, U. Stalder, J. A. Robinson
Chemistry Department, University of Zrich
Winterthurerstrasse 190, 8057 Zrich (Switzerland)
E-mail : robinson@oci.uzh.ch
[b] M. Juhas, L. Eberl
Department of Microbiology, Institute of Plant Biology, University of Zrich
Winterthurerstrasse 190, 8057 Zrich (Switzerland)
[c] A. Kaech, U. Ziegler
Center for Microscopy and Image Analysis, University of Zrich
Winterthurerstrasse 190, 8057 Zrich (Switzerland)
[d] D. Obrecht
Polyphor AG
Hegenheimermattweg 125, 4123 Allschwil (Switzerland)
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cbic.201200276: additional experimental proce-
dures and results, including figures and tables mentioned in the text.
Re-use of this article is permitted in accordance with the Terms and
Conditions set out at http://chembiochem.org/open.
ChemBioChem 2012, 13, 1767 – 1775  2012 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim 1767
to the OM in P. aeruginosa. Currently, no in vitro assay exists
for LPS transport by the purified LptD/E complex. Instead, we
have exploited methods used in earlier functional studies of
LptD/E in Gram-negative bacteria ; these involve monitoring
lipid A modifications that occur en-route to the OM.[2c,5]
LPS from P. aeruginosa contains lipid A (Figure 1C) linked to
a carbohydrate core that is in turn linked either to oligorham-
nose or to a highly immunogenic O-antigen polysaccharide.
The core–lipid A portion of LPS in most Gram-negative bacteria
is biosynthesised on the cytoplasmic side of the inner mem-
brane (IM). The core–lipid A is then flipped to the outer surface
of the IM by the ABC transporter MsbA, where more oligosac-
charides (oligorhamnose or the O-antigen) are added. How-
ever, before transport across the periplasm to the OM, two a-
hydroxylations of fatty acyl chains in lipid A can occur in P. aer-
uginosa (shown as X=H or OH in Figure 1C), catalysed by two
different Fe2+/a-ketoglutarate-dependent hydroxylases (LpxO
family of hydroxylases: genes PA4512 and PA1936).[5b] Only
a single lpxO gene is present in Salmonella spp., and this hy-
droxylase has been characterised biochemically in vitro.[6] How-
ever, no lpxO genes are present in Escherichia coli. LPS isolated
from laboratory strains of P. aeruginosa comprises mostly
mono- and some di-hydroxylated forms (see below).
Further tailoring modifications occur to lipid A after incorpo-
ration of LPS into the outer leaflet of the OM. LPS isolated
from laboratory strains of P. aeruginosa typically comprise
a penta-acyl form (2),[7] which lacks a 3-O-fatty acyl chain (com-
pare with 1, Figure 1C). The 3-O-deacylation step is catalysed
by the eight-stranded b-barrel enzyme PagL, which is integrat-
ed in the OM. The crystal structure of PagL from P. aeruginosa
reveals an active site with a Ser-His-Glu catalytic triad close to
the external OM surface.[8] Furthermore, and typically as part of
a membrane stress response to cationic antimicrobial peptides
or divalent metal ion limitation, a further modification can
occur to lipid A, catalysed by the b-barrel OM enzyme PagP.
PagP catalyses transfer of a palmitoyl group from a phospholip-
id to the b-OH of the 3’ O-acyl fatty acyl group, which increas-
es lipid A acylation (as in the hexa-acyl form 3, Figure 1C).[9] So-
lution and X-ray structures of the homologous PagP from
E. coli reveal an eight-stranded b-barrel, and an active site
again close to the extracellular side of the OM.[10]
Another lipid A modification that can occur on the IM in
P. aeruginosa, for example as part of a resistance mechanism to
cationic antimicrobial peptides, is addition of the sugar 4-
amino-4-deoxy-l-arabinose (AraN, 4) to one or both of the
1 and 4’-phosphate groups (Figure 1C).[11] P. aeruginosa isolates
from cystic fibrosis patients were shown to possess LPS modi-
fied by addition of one or two AraN sugars to the lipid A
core.[7a,d]
Figure 1. A) Structure of antibiotic L27–11. B) LPS transport in Pseudomonas aeruginosa. LPS assembly occurs in the cytoplasm and on the IM. Key tailoring
reactions occur either on the IM or the OM (see text). C) The conserved lipid A portion of LPS from P. aeruginosa. Structures: 1) before modification by PagL;
2) after the action of PagL; and 3) after the action of PagP. AraN sugar (4) can be added to the 1- and 4’-phosphate groups of lipid A.
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As these lipid A-modifying enzymes are located either in the
IM or OM, the corresponding lipid A modifications have often
been used as reporters for LPS trafficking within the bacterial
envelope.[2b, c, 5b] We make use of this here in an ESI-MS analysis
of lipid A isolated from P. aeruginosa exposed to L27–11. We
also prepared a conditional P. aeruginosa PAO1 lptD mutant, in
which expression of the lptD gene is controlled by the level of
rhamnose in the medium. With this mutant the effects of de-
pleting lptD can be compared with the effects of the antibiotic
on the wild-type strain. By these and other methods, our re-
sults support the hypothesis that the mode of action of the an-
tibiotic L27–11 involves inhibition of LptD-mediated LPS trans-
port to the cell surface. This most likely leads to major pertur-
bation of OM structure and morphology, as was detected by
EM in an earlier work.[1]
Results
Construction of an lptD conditional mutant.
In E. coli, lptD forms an operon with surA and pdxA (lptD-surA-
pdxA) that is transcribed from a sE-dependent promoter.[2a] A
similar organisation of overlapping lptD-surA-pdxA genes is
found in the P. aeruginosa chromosome (Figure 2A). A condi-
tional mutant was obtained by replacing the native lptD pro-
moter in the chromosome with the rhamnose-inducible pro-
moter PrhaB (see Figure 2B and the Experimental Section).
[12]
The conditional mutant, PAO1 PrhaBlptD, grew only in medium
containing rhamnose. In liquid LB medium with 0.5% glucose,
growth was strong when rhamnose (0.01% (w/v)) was pres-
ent, but was weak with 0.001% rhamnose (Figure S2). To
assess whether or not the cell envelope was compromised, flu-
orescent staining was carried out with Syto9 and propidium
iodide (LIVE/DEAD BacLight viability kit ; Molecular Probes/Invi-
trogen). Fluorescence microscopy of PAO1 PrhaBlptD cells grown
under permissive conditions (0.01% (w/v) rhamnose) re-
vealed green staining comparable to the PAO1 strain, whereas
under non-permissive conditions (0.001% (w/v) rhamnose),
most cells were stained red, thus suggesting a loss of viability
and a compromised cell envelope (Figure S3).
To investigate whether polar effects influence growth, the
conditional mutant was complemented in trans with different
regions of the lptD-surA-pdxA operon (see the Supporting In-
formation), by using the E. coli–Pseudomonas shuttle plasmid
pUCP-Nde.[13] Induction of the plasmid-borne lptD gene alone
with IPTG restored growth of the mutant under non-permissive
conditions (0.001% (w/v) rhamnose) to 70% of normal levels,
and for cells containing both lptD and surA genes, growth re-
turned to 90% of normal levels (Figure 2C). To compensate for
possible effects caused by loss of pdxA, growth media with or
without added vitamin B6 were used, but no significant effect
on growth under any conditions was observed. These experi-
ments confirmed that lptD is an essential gene for the growth
of P. aeruginosa PAO1.
To examine whether OM defects occur in the PrhaBlptD
mutant, growth on solid medium was monitored in the pres-
ence of 0.5% SDS and 0.5 mm EDTA, after introduction of
either lptD alone or the overlapping lptD-surA genes (Fig-
ure S4). Unlike the wild-type (wt) strain, the conditional mutant
was unable to grow on agar containing high rhamnose (0.1%
(w/v)) when SDS/EDTA were present, thus indicating OM sus-
ceptibility to the disruptive effects of detergent/EDTA. Comple-
mentation with lptD alone restored growth of the mutant to
wt levels on LB medium without rhamnose (as expected), but
again not when SDS/EDTA was present. However, complemen-
tation with lptD-surA genes allowed growth on LB agar plates
without rhamnose (and also in the presence of SDS/EDTA),
thus indicating that both genes are required to provide resist-
ance to detergent (Figure S4). This result is consistent with an
important function for SurA in the assembly of LptD/E in P. aer-
uginosa.
Analysis of lipid A from antibiotic-treated P. aeruginosa
Lipid A derived from P. aeruginosa PAO1 LPS was analysed by
high-resolution (HR) ESI-MS and by HR-ESI-MS/MS methods in
negative-ion mode. The results are shown in Figure 3 and in
Table S1 and S2. Normal growth in Mueller–Hinton (MH)
medium afforded lipid A: ESI-MS m/z 714.4 and 722.4 for the
Figure 2. A) Overlapping lptD, surA and pdxA probably form an operon in
P. aeruginosa. B) Construction of the lptD conditional mutant. After integra-
tion of the plasmid into the chromosome, lptD is under control of a rham-
nose promoter (PrhaB). Red depicts the promoter region of lptD ; green
arrows show the locations of primers used for PCR to confirm the site of
integration. C) Complementation of the mutant. OD600 values at two time
points (11 and 24 h) during growth of the mutant containing: (A and D)
empty vector pUCP-Nde, (B and E) vector with lptD, and (C and F) vector
with lptD+ surA. (A–C: high, 0.1% (w/v), rhamnose, D–F: low, 0.001% (w/v)
rhamnose, mutants with lptD or lptD+ surA showed strong growth after
24 h).
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doubly charged [M2H]2 ion (calcd mass 1430.9 and 1446.9)
corresponding to penta-acyl form 2 (non- and monohydroxy-
lated, X=H,H and X=H,OH Figure 1C); smaller peaks at m/z
799.5/807.5 corresponding to the hexa-acyl form 1 (non- and
mono-hydroxylated); and a small peak at m/z 841.5 corre-
sponding to the hexa-acyl form 3 (mono-hydroxylated;
Figure 3, spectrum A). The structure assignments and relative
proportions were confirmed by HR-ESI-MS (Table S1) and by
HR-ESI-MS/MS measurements (Table S2).
This pattern of lipid A molecules changed rapidly when anti-
biotic L27–11 was added to liquid culture in MH broth. After
1.25 h, new peaks were seen (Figure 3, spectrum B) because of
accumulation of 1 (m/z 807.5/815.5), as well as 1 containing
one or two AraN sugars (m/z 873.0/881.5/938.5/946.5), and
there was an increased proportion of the hexa-acyl form 3
(m/z 841.5/849.5). Moreover, the ratio of di- to mono-hydroxy-
lated lipid A species increased because of a higher extent of di-
hydroxylation in the IM (Table S1). After 6 h growth in medium
containing L27–11, the hexa-acyl form 1, which was mainly di-
hydroxylated with 2 AraN sugars (m/z 938.5/946.5), was pre-
dominant (Figure 3, spectrum C). These results demonstrate
rapid accumulation of LPS forms in antibiotic-treated cells that
have not been processed by PagL.
In contrast, addition of the enantiomer of L27–11 (ent-L27–
11) to growth medium did not inhibit bacterial growth and
caused only a slow change in the lipid A profile: after 6 h,
lipid A 2 containing two AraN sugar units predominated
(Figure 3, spectrum D and Table S1), and this had been pro-
cessed by PagL. This result also shows that the presence of
AraN sugars does not prevent processing by PagL, in agree-
ment with earlier studies.[7d]
Analysis of lipid A from the PAO1 PrhaBlptD mutant
To test whether down-regulation of lptD produces effects on
lipid A modification that are similar to those induced by the
antibiotic, lipid A was prepared from the conditional PAO1
PrhaBlptD mutant grown with high rhamnose and analysed by
ESI-MS. The MS spectrum (Figure 3, spectrum E and Table S1)
showed a major peak at m/z 722.4 (lipid A species 2) and
a smaller peak at m/z 807.5 (species 1), similar to that of spec-
trum A for wt PAO1. However, when the mutant was grown in
the presence of limiting rhamnose to deplete LptD, bacterial
growth was slower, and the extracted lipid A gave peaks
mainly attributable to lipid A species 1 with mono- or dihy-
droxylation and one or two AraN sugars (m/z 881.0/938.5/
946.5; Figure 3, spectrum F, and Table S1). Thus, down-regula-
Figure 3. Negative mode ESI-MS spectra showing doubly-charged ions from lipid A species (see Table S1) isolated from P. aeruginosa PAO1; A) grown in MH
broth; B) grown with antibiotic L27–11 for 1.25 h; C) grown with L27–11 for 6 h; D) grown with enantiomer of L27–11. PAO1 PrhaBlptD grown with E) high
rhamnose, and F) low rhamnose. The assignments of key peaks are derived from HR-ESI-MS and HR-ESI-MS/MS measurements (see the Supporting Informa-
tion). Cartoons as shown in Figure 1.
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tion of lptD leads to the accumulation of lipid A forms that are
not processed by PagL, as was the case for antibiotic-treated
cells (Spectra B/C).
EM studies of the PAO1 PrhaBlptD mutant
We reported earlier that P. aeruginosa PAO1 grown in MH
broth with L27–11 revealed unusual internal accumulations of
membrane-like material in thin sections by transmission EM.[1]
The PAO1 PrhaBlptD mutant examined in the same way after
growth in LB medium revealed normal cell morphology for
cells grown with high rhamnose (+lptD), but again internal
accumulations of membrane-like material appeared in sections
of cells grown with depleted LptD (lptD ; Figure 4A).
In scanning EM images, P. aeruginosa PAO1 cells grown in
the presence of the antibiotic L27–11 appeared to have many
external protrusions/blebbing of the OM (wt PAO1 with L27–
11); these were not seen when cells were grown normally in
MH broth (wt PAO1) (Figure 4B). A similar blebbing of the OM
was also observed when the PAO1 PrhaBlptD mutant was grown
with depleted LptD (lptD ; Figure 4B), but not when lptD ex-
pression was induced with high rhamnose (+lptD). These stud-
ies revealed dramatic effects on membrane morphology by the
actions of the antibiotic L27–11, similar to those caused by
depletion of LptD.
Labelling LPS with [14C]acetate
The effects of the antibiotic on LPS transport in cultures of
P. aeruginosa were investigated by monitoring the incorpora-
tion of [14C]acetate into LPS. [1-14C]acetate was added to P. aer-
uginosa grown in MH broth. After 3 h, lipid A was extracted
and analysed by TLC and autoradiography. TLC spots were
identified in direct TLC-MALDI MS analyses: one major radioac-
tive spot on the TLC plate from 14C-labelled penta-acyl lipid A
species 2 (Figure 5, lane 1). When [1-14C]acetate was added to
growing cells along with EDTA, the major labelled lipid A was
the hexa-acyl form 3 (Figure 5, lane 2). This result is consistent
with the known effect of EDTA on the OM. EDTA extracts metal
ions and weakens interactions between LPS molecules, thereby
allowing phospholipids into the outer leaflet, which in turn ac-
tivates PagP.[14] When the antibiotic L27–11 and [1-14C]acetate
were added to growing cultures, the major 14C-labelled lipid A
observed was the 14C-hexa-acyl form 1 containing two AraN
sugar residues (Figure 5, lane 3). Only weak labelling of the
normal penta-acyl form 2 and the hexa-acyl form 3 was ob-
served in these experiments. This result demonstrates 14C pref-
erentially incorporates into LPS that has not been modified by
PagL.
Analysis of IM and OM components
The effects of the antibiotic on the membrane composition of
P. aeruginosa PAO1 were analysed by sucrose density gradient
analytical ultracentrifugation (Figure 6).[15] The lighter IM frac-
tions (18–21) possessed the characteristic red colour of cyto-
chromes and contained NADH oxidase activity, while the
denser OM fractions (1–5) appeared translucent white; they
also contained LptD, as detected by immunoblotting with anti-
LptD antibodies, as in an earlier report.[15b] LPS was found con-
centrated largely in the heavy OM fraction. When cells were
grown with sodium [1-14C]acetate, two clear 14C peaks were
observed, one in the IM fractions of the gradient (19–22), and
the other in the OM fractions (2–5; Figure 6).
When cells grown in MH broth with L27–11 (1 mgmL1) were
harvested after 5 h (OD6000.8–1.0), a clear separation of IM
and OM components was not
observed; no distinct red and
white translucent bands were
apparent in the light and heavy
fractions of the gradient; the
total protein concentration and
location of LptD were skewed
towards lighter fractions, and
a single peak of greatly reduced
NADH oxidase activity appeared
closer to the centre of the gradi-
ent; levels of incorporated 14C
were much higher than with un-
treated cells, and labelled LPS
was skewed more towards the
Figure 4. A) Transmission EM of sections of PAO1 PrhaBlptD cells with LptD induced (+ lptD) and depleted (-lptD),
showing accumulation of membranous material in the latter (scale bar=200 nm). B) Scanning EM of wt PAO1
grown with and without antibiotic L27–11 (left), and of PAO1 PrhaBlptD mutant (right) with lptD induced (top) or
depleted (bottom), showing blebbing of the membrane only when antibiotic is present, or lptD is depleted (scale
bar=1 mm).
Figure 5. Autoradiograms showing 14C-labelled lipid A from P. aeruginosa
PAO1 grown in MH broth and separated by TLC (Supporting Information)
after incorporation of [1-14C]acetate. Lane 1: lipid A from PAO1 grown in MH
broth; lane 2: lipid A from cells grown with addition of [1-14C]-acetate and
EDTA; lane-3: addition of [1-14C]acetate, then antibiotic L27–11 (1 mgmL1),
and growth for 2 h. The lipid A species 1, 2 and 3 (Figure 1) are indicated.
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lighter fractions. These results indicate that the IM and OM
cannot be cleanly separated from cells treated in this way.
However, when PAO1 cells were exposed to the antibiotic for
a much shorter time (15–30 min), fractionation of the IM and
OM components was still possible. A red band and NADH ox-
idase activity were then still concentrated in the IM fractions,
and LptD was found in the OM fractions; however, more LPS
was found associated with lighter (IM) fractions in the sucrose
gradient (Figure 6, bottom). Also, when both [14C]acetate and
L27–11 were added to culture, 14C-labelled LPS was skewed to-
wards the lighter IM fractions in the sucrose gradient, com-
pared to cells not exposed to the antibiotic, consistent with
partial inhibition of LPS transport to the OM.
Discussion
LptD is an essential OM protein in E. coli that is required for
the biogenesis of the cell envelope.[2a] Initial evidence for the
role of LptD in OM assembly came from studies in Neisseria
meningitides, where its deletion is tolerated and results in loss
of LPS transport to the cell surface.[2b] LptD was later found to
exist in a complex with the essential OM lipoprotein LptE in
E. coli, where both proteins are required for LPS transport to
the cell surface.[2c, e, 16] All the Lpt proteins needed for LPS bio-
synthesis and transport from the cytoplasm in E. coli have now
been identified, including LptA, which facilitates LPS transport
across the periplasm and delivery to LptD/E in the OM.[2d,17]
We first set out to construct a conditional lptD mutant,
which could be used to investigate the effects of depleting
LptD in P. aeruginosa. LptD is essential for growth in E. coli, but
not in N. meningitides or Helicobacter pylori.[2b,18] Attempts to
create a knock-out mutant by insertional inactivation of lptD in
P. aeruginosa PAO1 by means of a suicide vector containing
internal fragments failed to provide viable mutants, thus sug-
gesting that lptD is an essential gene in P. aeruginosa. A PAO1
conditional knock-out mutant was obtained by replacing the
natural promoter of lptD in the chromosome with the rham-
nose-inducible promoter PrhaB.
[12] This change, however, likely
affects expression of the entire operon of overlapping lptD-
surA-pdxA genes (Figure 2). The overlapping arrangement of
lptD and surA is conserved in Gram-negative bacteria.[19]
SurA is a periplasmic chaperone that plays an important role
in the assembly of the LptD/E complex in E. coli.[20] Strains lack-
ing SurA exhibit defects that are indicative of OM perturba-
tions,[21] and are hypersensitive to detergents and hydrophobic
antibiotics.[22] Loss of SurA can be partly compensated for by
other periplasmic chaperones such as Skp, but SurA plays an
important role in folding of LptD in the OM in E. coli.[20] Hence,
it was of interest to investigate whether loss of SurA has simi-
lar effects in P. aeruginosa. Growth of the conditional PrhaBlptD
mutant near to wt levels occurred only with high rhamnose in
the medium, or with low rhamnose when the mutant was
complemented in trans by lptD, thus showing that lptD is an
essential gene in P. aeruginosa. However, under low rhamnose
conditions, complementation of the mutant with both lptD
and surA was required to restore wt levels of resistance to
external detergent (SDS/EDTA). This is consistent with an im-
portant role for SurA in the assembly of LptD also in P. aerugi-
nosa.[20]
The perturbation in membrane structure arising from deple-
tion of LptD was visible by transmission EM as extensive fold-
ing into the cytoplasm of the IM (Figure 4A), perhaps caused
by accumulation of LPS within the IM. Similar accumulations of
“extra” membrane material were reported earlier within E. coli
cells upon depletion of LptD and LptA,[2c,23] and in P. aeruginosa
after treatment with antibiotic L27–11.[1] In addition, pro-
nounced blebbing of the OM was seen in scanning EM images
of both LptD-depleted and antibiotic-treated cells (Figure 4B).
Blebbing and outer membrane vesicle formation in P. aerugino-
sa and E. coli are known to be stimulated by envelope stress.[24]
The blebbing appears to occur randomly over the outer cell
surface, and might conceivably be caused by a combination of
factors, such as insertion of phospholipids into the outer leaf-
let, thereby resulting in weakened interactions between LPS
molecules, which result in OM instability.
Four different approaches were followed to obtain evidence
that the antibiotic L27–11 inhibits LptD-mediated LPS transport
Figure 6. Top: Fractionation of IM and OM by sucrose gradient ultracentrifu-
gation from P. aeruginosa PAO1 grown in MH broth with [1-14C]acetate but
without antibiotic. Bottom: Repeat of IM and OM fractionation 30 min after
co-addition of [1-14C]acetate and L27–11 [1 mgmL1] to cells grown in MH
broth. Fractions (1–22) were taken from the bottom of the gradient and ana-
lysed for total protein content (& [mgmL1]), NADH oxidase activity (* [units
 50000 per 150 mL]) and incorporated radioactivity (~ [DPM20 per
50 mL]). A) LPS in SDS-PAGE detected by silver staining. B) LptD detected by
immunoblotting. C) Radioactive LPS in SDS-PAGE gels detected by autora-
diography.
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to the OM in P. aeruginosa. First, modifications to the lipid A
core of LPS induced during cell growth with the antibiotic, or
after depletion of lptD in the conditional mutant, were ana-
lysed by ESI-MS. As mentioned in the introduction, several
lipid A modification systems have been shown to exist in P. aer-
uginosa. The bacterium can modify LPS within the OM cova-
lently by using enzymes PagL and PagP.[25] In addition, genes
PA4512 and PA1936 in P. aeruginosa PAO1 encode homologues
of LpxO, each of which likely a-hydroxylates one of the 2’- and
2-secondary acyl chains in lipid A.[25] Lipid A from PAO1 might,
therefore, contain none, one or two a-hydroxy groups (X=H
or OH, Figure 1C), depending upon the extent of turnover by
these two IM hydroxylases. The major penta-acylated form of
lipid A (2, mass of 1447) corresponds to lipid A that has under-
gone a single a-hydroxylation. A third type of modification to
lipid A involves addition of the sugar AraN. P. aeruginosa con-
tains numerous OM sensor kinases that allow cells to respond
to various environmental signals, including low levels of diva-
lent metal ions, the presence of cationic antimicrobial peptides
and other causative agents of membrane stress. These include
the PhoP/Q, PmrA/B and the ParR/S two-component regulatory
systems that can up-regulate the expression of genes for the
biosynthesis of AraN and its addition to the lipid A core of
LPS.[26] For example, growth of PAO1 in low Mg2+ medium pro-
motes addition of AraN to the 1 and/or 4’ phosphates of lipid
A.[7d] In E. coli and Salmonella typhimurium an IM enzyme
(ArnT) adds one or two AraN sugars to lipid A, most likely on
the periplasmic side of the IM,[27] and a homologue of ArnT
exists also in P. aeruginosa PAO1. It was shown earlier that
modification of LPS with AraN can occur in combination with
3-O-deacylation by PagL in P. aeruginosa,[7d] unlike in S. typhi-
murium, where PagL is inhibited by modification of LPS with
AraN.[28] Here, we showed that the enantiomer of L27–11 (ent-
L27–11), which shows only weak antimicrobial activity with
P. aeruginosa PAO1 (MIC 32 mgmL1), could lead to accumula-
tion of LPS that had been modified by PagL and by addition of
AraN (Figure 3D), thus confirming the finding of the earlier
study: that modification with AraN can occur in combination
with 3-O-deacylation by PagL.[7d]
Modifications catalysed by PagL and PagP in the OM, and by
ArnT and LpxO1/2 in the IM, are therefore useful markers for
LPS en route to the OM. The ESI-MS of lipid A measured under
conditions that promote negative ion formation revealed that
the most abundant form of lipid A isolated from PAO1 was the
expected penta-acyl form (2, monohydroxylated, modified by
PagL), although small amounts of the hexa-acyl form (3, mono-
hydroxylated, modified by PagP) was also detected (Figure 3
and Table S1). After cell growth in the presence of antibiotic
L27–11, the lipid A profile changed, with the rapid emergence
of hexa-acyl lipid A forms (1) that are not modified by PagL or
PagP, are twice hydroxylated and twice modified with addition
of AraN. These changes are consistent with retention of in-
creasing amounts of LPS in the IM when antibiotic is present.
Lipid A isolated from the conditional PAO1 PrhaBlptD mutant
grown with high rhamnose comprised the penta-acyl form (2,
mono-hydroxylated), although small amounts of 2 with
a single AraN units were also detected (Figure 3 and Table S1).
Under low rhamnose conditions, however, the major lipid A
detected by ESI-MS was the hexa-acyl form (1, dihydroxylated)
with two AraN sugars (Figure 3 and Table S1). Thus, growth of
P. aeruginosa PAO1 with antibiotic L27–11 leads to similar
lipid A modifications as those that are observed in the condi-
tional mutant when LptD is depleted. Complementary data
were obtained by monitoring the incorporation of 14C from [1-
14C]acetate into LPS in the presence of antibiotic (Figure 5).
Under normal growth conditions (without antibiotic), forma-
tion of mainly 14C-lipid A 2 was observed, while with EDTA
present, mainly the 14C-palmitoylated lipid A form 3 was ob-
served, because of the action of PagP. However, with antibiotic
present, the profile of modified 14C-lipid A changed, with accu-
mulation of the 14C-hexa-acyl form 1 that contains two AraN
sugars.
Transport of LPS was also investigated by separating the IM
and OM by sucrose gradient utracentrifugation. However,
when PAO1 cells were exposed to L27–11, it quickly became
impossible to obtain clear separation of IM and OM compo-
nents, most likely attributable to major concomitant changes
in membrane structure and morphology, as detected by EM.
Similar observations have been made when LptD, LptA or LptB
was depleted in E. coli.[17b,23] This further underscores the simi-
lar effects elicited by the antibiotic and by depletion of LptD.
Nevertheless, by exposing PAO1 cells to the antibiotic for only
short times, fractionation of the IM and OM components was
still possible, and under these conditions a trend was apparent,
with a skewing of LPS (including 14C-labelled LPS de novo bio-
synthesised from [1-14C]-acetate) from the OM fractions to-
wards the IM (Figure 6).
The results reported here are not consistent with LptD
acting merely to transport L27–11 across the OM, but rather
support a mechanism of action for the antibiotic that involves
inhibition of LptD-mediated LPS transport to the OM. Many de-
tails of this mechanism of action remain to be elucidated, not
least how and where the antibiotic binds to the folded LptD
protein, and how this binding event is linked to inhibition of
LPS transport. LptD plays an essential role in OM biogenesis in
many Gram-negative bacteria. The peptidomimetics act selec-
tively against Pseudomonas sp., perhaps depending on se-
quence and/or structural differences in LptD between different
Gram-negative bacteria. So far the 3D structure and mode of
action of LptD are unknown. However, the conserved domain
organisation and exposed location in the OM suggest that
LptD might nevertheless be an interesting target in screening
efforts to discover new drugs active against other Gram-nega-
tive pathogens. Available inhibitors of LptD, such as L27–11,
might also serve as molecular tools for more detailed mecha-
nistic studies of LPS transport. Finally, information on the
mechanism of action of these antibiotics is crucial for their clin-
ical development. The first clinical candidate, POL7080, has al-
ready been identified and has now entered a phase I human
clinical trial.
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Experimental Section
Bacterial strains and plasmids: Bacterial strains, plasmids and
oligonucleotides are described in the Supporting Information.
Construction and complementation of the PrhaBlptD mutant:
A fragment (~300 bp) spanning the 5’ region of lptD was am-
plified by PCR with primers lptDcm-F and lptDcm-R, homolo-
gous to regions around, and downstream of, the start codon.
The PCR product was digested with NdeI and XbaI and cloned
into XbaI-digested pSC200Gm,[29] downstream of PrhaB (Fig-
ure 2B). The resulting plasmid was introduced into E. coli
CC118 l pir with selection on gentamicin (Gm; 25 mgmL1)
and glucose (0.5%). The plasmid was then transferred into
P. aeruginosa PAO1 by triparental mating, with selection of the
conditional mutant on PIA (Difco) medium supplemented with
rhamnose (0.5%) and Gm (150 mgmL1). The primer pair test1/
test2 was used to confirm by PCR that the plasmid had inte-
grated at the expected site in the chromosome (see Figure 2B
and Figure S1). The methods used to complement the PrhaBlptD
mutant with plasmid-borne copies of lptD or overlapping lptD
and surA are given in the SI.
Growth and viability of the PrhaBlptD mutant: Growth charac-
teristics and viability of the mutant, including Live/Dead stain-
ing and susceptibility to SDS/EDTA, are shown in Figures S2
and S3. The mutant was unable to grow with glucose on agar
plates or in liquid medium. Growth was weak in the presence
of low rhamnose (0.001% (w/v)), but in liquid medium and
agar with high rhamnose (0.01%), growth occurred as for the
wt strain (Figure S2).
Isolation and analysis of lipid A: LPS was isolated from P. aer-
uginosa by the hot phenol–water extraction method.[30] Lipid A
was prepared from LPS by hydrolysis in sodium acetate
(pH 4.5), and then isolated using the method of Bligh–Dyer.[31]
Briefly, cells from culture broth (40 mL, OD600=1.0) were har-
vested by centrifugation (4 8C, 3500g) and washed twice with
phosphate-buffered saline (PBS; 5 mL, NaH2PO4 (2.5 mm),
Na2HPO4 (7.5 mm), NaCl (145 mm), pH 7.2). The pellet was re-
suspended in PBS (0.8 mL, pH 7.2) and a mixture of MeOH
(2 mL) and CHCl3 (1 mL) was added. After 60 min the insoluble
material was collected by centrifugation (4 8C, 3500g). The
pellet was washed with CHCl3/MeOH/H2O (1:2:0.8 (v/v/v),
5 mL), and suspended in sodium acetate buffer (1.8 mL,
12.5 mm, pH 4.5), containing SDS (1% (w/v)) with agitation.
The mixture was heated in a boiling water bath for 30 min to
cleave the glycosidic linkage between Kdo and lipid A. MeOH
(2 mL) and CHCl3 (2 mL) were added to the hydrolysed materi-
al, and, after centrifugation (5 min, 200g), the lower phase
(mainly CHCl3) was collected and washed twice with CHCl3/
MeOH/H2O (2:2:1.8, v/v/v, 4 mL). The washed lower phase was
dried under a stream of N2 and stored at 20 8C. Details of the
TLC separation of lipid A and conditions for analysis by MS are
provided in the Supporting Information.
Membrane fractionation by ultracentrifugation: Fractionation
of IM and OM components by sucrose gradient ultracentrifuga-
tion was as described elsewhere.[15b] Fractions taken from the
bottom of the sucrose gradient were analysed for NADH oxida-
tion activity as described;[32] protein concentrations were deter-
mined by using a Pierce BCA protein assay kit (Thermo Scien-
tific) ; LPS was analysed by 15% SDS-PAGE in Tris-HCl buffer
(0.1m, pH 6.8) containing SDS (2%), sucrose (20%), 2-mercap-
toethanol (1%) and bromophenol blue (0.001%); LPS was
detected in gels by silver staining;[33] LptD was detected by
immunoblotting with anti-LptD polyclonal antibodies as de-
scribed.[1]
Electron microscopy: The methods used to prepare samples
for EM were as previously described,[1] and in the Supporting
Information.
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